非选择性β-受体阻滞剂在肝硬化患者中的应用进展

刘晓燕; 苏海滨

doi:10.3969/j.issn.1001-5256.2017.11.036

非选择性β-受体阻滞剂在肝硬化患者中的应用进展

DOI: 10.3969/j.issn.1001-5256.2017.11.036

解放军第三○二医院肝衰竭诊疗与研究中心

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1920
- HTML全文浏览量: 11
- PDF下载量: 366
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-09
- 出版日期: 2017-11-20

Application of non-selective β-blockers in patients with liver cirrhosis

Liver Failure Treatment and Research Center, 302 Hospital of PLA

摘要

摘要: 非选择性β-受体阻滞剂（NSBBs）可有效降低肝静脉压力梯度,是肝硬化合并食管胃底静脉曲张破裂出血的一级和二级预防的一线用药,此外还可减轻重症肝病患者的炎性反应。但在肝硬化合并顽固性腹水、原发性细菌性腹膜炎以及肾功能损伤患者中的应用仍存在很大争议。因此,NSBBs用于预防食管静脉破裂出血时有窗口期,且用药剂量因人而异。此外,NSBBs还有心源性或非心源性副作用,用药时必须监测副反应,随时调整剂量。综述了NSBBs在预防食管胃底静脉破裂出血方面的最新研究进展。
- 肝硬化 /
- 高血压,门静脉 /
- 非选择性β-受体阻滞剂 /
- 食管和胃静脉曲张 /
- 综述
Abstract: Non-selective β-blockers (NSBBs) can effectively reduce hepatic venous pressure gradient (HVPG) , and are the first-line drugs for primary and secondary prevention of liver cirrhosis complicated by esophagogastric variceal bleeding.In addition, NSBBs can alleviate inflammatory response in patients with severe liver diseases.However, there are still controversies over the use of NSBBs in patients with liver cirrhosis complicated by intractable ascites, primary bacterial peritonitis, or kidney dysfunction.Therefore, NSBBs have a window period in the prevention of esophageal variceal bleeding with varying doses.Moreover, NSBBs have cardiogenic or non-cardiogenic side-effects, and thus side-effects should be closely monitored and the dose should be adjusted.This article reviews the latest research advances in NSBBs in preventing esophagogastric variceal bleeding.
- liver cirrhosis /
- hypertension, portal /
- non-selective-blockers /
- esophageal and gastric varices /
- review

HTML全文

参考文献(45)

[1]MOOKERJEE RP, PAVESI M, THOMSEN KL, et al.Treatment with non-selective beta-blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure[J].J Hepatol, 2016, 64 (3) :574-582.

[2]BURROUGHS AK, THALHEIMER U.Hepatic venous pressure gradient in 2010[J].Hepatology, 2010, 51 (6) :1894-1896.

[3]RIPOLL C, GROSZMANN R, GARCIA-TSAO G, et al.Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J].Gastroenterology, 2007, 133 (2) :481-488.

[4]GE PS, RUNYON BA.The changing role of beta-blocker therapy in patients with cirrhosis[J].J Hepatol, 2014, 60 (3) :643-653.

[5]AL-GHAMDI H.Carvedilol in the treatment of portal hypertension[J].Saudi J Gastroenterol, 2011, 17 (2) :155-158.

[6]GLUUD LL, KRAG A.Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults[J].Cochrane Database Syst Rev, 2012, 15 (8) :cd004544.

[7]LO GH, CHEN WC, LIN CK, et al.Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding[J].Hepatology, 2008, 48 (2) :580-587.

[8]de FRANCHIS R, Baveno VI Faculty.Expanding consensus in portal hypertension:report of the Baveno VI Consensus Workshop:stratifying risk and individualizing care for portal hypertension[J].JHepatol, 2015, 63 (3) :743-752.

[9]VILLANUEVA C, ARACIL C, COLOMO A, et al.Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding[J].Gastroenterology, 2009, 137 (1) :119-128.

[10]HERNANDEZ-CEA V, ARACIL C, COLOMO A, et al.Development of ascites in compensated cirrhosis with severe portal hypertension treated with B-blockers[J].Am J Gastrocnterol, 2012, 107 (3) :418-427.

[11]ABRALDES JG, TARANTINO I, TURNES J, et al.Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis[J].Hepatology, 2003, 37 (4) :902-908.

[12]BOSCH J.Carvedilol for portal hypertension in patients with cirrhosis[J].Hepatology, 2010, 51 (6) :2214-2218.

[13]RERBERGER T, ULBRICH G, FERLITSCH A, et al.Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranol[J].Gut, 2013, 62 (11) :1634-1641.

[14]HOBOLTH L, MФLLER S, GRФNBK H, et al.Carvedilal or propranolal in portal hypertonsioa:a randomized comparison[J].Seand J Gastroenterel, 2012, 47 (4) :467-474.

[15]SINAGRA E, PERRICONE G, D'AMICO M, et al.Systematic review with meta-analysis:the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J].Aliment Pharmacol Ther, 2014, 39 (6) :557-568.

[16]LIN HC, YANG YY, HOU MC, et al.Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis[J].Am J Gastroenterol, 2004, 99 (10) :1953-1958.

[17]STANLEY AJ, DICKSON S, HAYES PC, et al.Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding[J].J Hepatol, 2014, 61 (5) :1014-1019.

[18]BHARDWAJ A, KEDARISETTY CK, VASHISHTHA C, et al.Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis:a randomised placebo-controlled trial[J].Gut, 2016.pii:gutjnl-2016-311735.

[19]MANDORFER M, PECK-RADOSAVLJEVIC M, REIBERGERT.Prevention of progression from small to large varices:are we there yet?An updated meta-anaylsis[J].Gut, 2016, 66 (7) :1347-1349.

[20]GE PS, RUNYON BA.Beta-blockers in cirrhosis:thank you for your attention[J].J Hepatol, 2014, 61 (2) :451-452.

[21]REIBERGER T, FERLITSCH A, PAYER BA, et al.Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis[J].J Hepatol, 2013, 58 (5) :911-921.

[22]MERLI M, LUCIDI, C, di GREGORIO V, et al.The chronic use of betablockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis[J].Liver Int, 2015, 35 (2) :362-369.

[23]BRITO-AZEVEDO A, PEREZ RDE M, COELHO HS, et al.Propranolol improves endothelial dysfunction in advanced cirrhosis:the'endothelial exhaustion'hypothesis[J].Gut, 2016, 65 (8) :1391-1392.

[24]USTUNDAG Y, SARITAS U.Non-selective beta-blockers for the patients with acute on chronic liver failure[J].J Hepatol, 2016, 65 (3) :645-649.

[25]REIBERGER T, FERLITSCH A, PAYER BA, et al.Non-selective beta-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis[J].J Gastroenterol, 2012, 47 (5) :561-568.

[26]MEHVAR R, BROCKS DR.Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans[J].J Pharm Pharm Sci, 2001, 4 (2) :185-200.

[27]WALLE T, WALLE UK, COWART TD, et al.Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects[J].Clin Pharmacol Ther, 1989, 46 (3) :257-263.

[28]CARDENAS A, MENDEZ-BOCANEGRA A.Report of the Baveno VI Consensus Workshop[J].Ann Hepatol, 2016, 15 (2) :289-290.

[29]ABBAS M, KHAN AM, RIFFAT S, et al.Assessment of sex differences in Pharmacokinetics of carvedilol in human[J].Pak J Pharm Sci, 2014, 27 (5) :1265-1269.

[30]OTEY CR, BANDARA G, LALONDE J, et al.Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450[J].Biotechnol Bioeng, 2006, 93 (3) :494-499.

[31]JOHNSON JA, HERRING VL, WOLFE MS, et al.CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences[J].J Pharmacol Exp Ther, 2000, 294 (3) :1099-1105.

[32]ZHANG F, DUAN X, ZHANG M, et al.Influence of CYP2D6andbeta2-adrenergic receptor gene polymorphisms on thehemodynamic response to propranolol in Chinese Han patients with cirrhosis[J].J Gastroenterol Hepatol, 2016, 31 (4) :829-834.

[33]SERSTE T, MELOT C, FRANCOZ C, et al.Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J].Hepatology, 2010, 52 (3) :1017-1022.

[34]MANDORFER M, BOTA S, SCHWABL P, et al.Nonselectiveβblockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis[J].Gastroenterology, 2014, 146 (7) :1680-1690.

[35]GARCIA-TSAO G.Beta blockers in cirrhosis:the window re-opens[J].J Hepatol, 2016, 64 (3) :532-534.

[36]GROSZMANN RJ, GARCIA-TSAO G, BOSCH J, et al.Betablockers to prevent gastroesophageal varices in patients with cirrhosis[J].New Engl J Med, 2005, 353 (21) :2254-2261.

[37]VILLANUEVA C, ALBILLOS A, GENESCA J, et al.Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension[J].Hepatology, 2015, 63 (1) :197-206.

[38]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Endoscopy, Chinese Medical Association.Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J].J Clin Hepatol, 2016, 32 (2) :203-219. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].临床肝胆病杂志, 2016, 32 (2) :203-219.

[39]KALAMBOKIS GN, CHRISTODOULOU D, BALTAYIANNIS G, et al.Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites[J].Hepatology, 2016, 64 (5) :1806-1808.

[40]TURON F, CASU S, HERNNDEZ-GEA V, et al.Variceal and other portal hypertension related bleeding[J].Best Pract Res Clin Gastroenterol, 2013, 27 (5) :649-664.

[41]LEITHEAD JA, RAJORIYA N, TEHAMI N, et al.Non-selectiveβ-blockers are associated with improved survival in patients with ascites listed for liver transplantation[J].Gut, 2015, 64 (7) :1111-1119.

[42]BOSSEN L, KRAG A, VILSTRUP H, et al.Nonselectiveβ-blockers do not affect mortality in cirrhosis patients with ascites:Post Hoc analysis of three randomized controlled trials with 1198 patients[J].Hepatology, 2016, 63 (6) :1968-1976.

[43]LEE WG, MURPHY R, MCCALL JL, et al.Nadolol reduces insulin sensitivity in liver cirrhosis:a randomized double-blind crossover trial[J].Diabetes Metab Res Rev, 2017, 33 (3) :e2859.

[44] BAKRIS GL, FONSECA V, KATHOLI RE, et al.Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial[J].JAMA, 2004, 292 (18) :2227-2236.

[45]BASAT O, UCAK S, SEBER S, et al.After myocardial infarction carvedilol improves insulin resistance compared to metoprolol[J].Clin Res Cardiol, 2006, 95 (2) :99-104.

施引文献

资源附件(0)

访问统计